Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparative Precision of 3D MRE and 2D MRE for Measurement of Liver Stiffness in Adults with Severe Obesity.

Radiology·2026

Same author

Therapeutic Potential of Mesenchymal Stem Cells in Stroke Treatment.

Biomolecules·2025

Same author

Induced Mesenchymal Stem Cells: An Emerging Source for Regenerative Medicine Applications.

Journal of clinical medicine·2025

Same author

Proton density fat fraction for diagnosis of metabolic dysfunction-associated steatotic liver disease.

Hepatology (Baltimore, Md.)·2025

Same author

CRISPuRe-seq: pooled screening of barcoded ribonucleoprotein reporters reveals regulation of RNA polymerase III transcription by the integrated stress response via mTOR.

Nucleic acids research·2025

Same author

CRISPuRe-seq: pooled screening of barcoded ribonucleoprotein reporters reveals regulation of RNA polymerase III transcription by the integrated stress response via mTOR.

Nucleic acids research·2025

Same journal

Glandular odontogenic cyst: a case report in an asymptomatic patient.

Journal of experimental therapeutics & oncology·2019

Same journal

Cervical carcinosarcoma presented in advanced stage after high grade cervical displasia.

Journal of experimental therapeutics & oncology·2019

Same journal

Clear cell variant of Oral Squamous cell carcinoma.

Journal of experimental therapeutics & oncology·2019

Same journal

Giant Cervicodorsal Schwannoma.

Journal of experimental therapeutics & oncology·2019

Same journal

Effectiveness of structured teaching programme on knowledge and practice regarding care of children with leukemia among mothers.

Journal of experimental therapeutics & oncology·2019

Same journal

Clinico-pathological presentation of breast carcinoma and its correlation with β hCG.

Journal of experimental therapeutics & oncology·2019

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Chimeric antigen receptors for stem cell based immunotherapy.

Michael S Badowski¹, Tong Zhang, Tom C Tsang

¹Department of Immunobiology, PO Box 245221, The University of Arizona, Tucson, AZ 85724, USA.

Journal of Experimental Therapeutics & Oncology

|October 16, 2009

Summary

This summary is machine-generated.

Researchers developed novel chimeric receptors targeting HER2/neu for cancer immunotherapy. These molecules can be expressed in hematopoietic stem cells, offering new tools for retargeting lymphocytes and studying immune cell function.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Experiment Videos

Last Updated: Jun 19, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Area of Science:

Immunotherapy
Molecular Biology
Oncology

Background:

Lymphocyte retargeting is a key strategy in cancer immunotherapy.
High-affinity specificities from antibodies and T-cell receptors (TCRs) can be engineered for therapeutic applications.
HER2/neu is an overexpressed tumor antigen in certain cancers.

Purpose of the Study:

To develop novel molecules for retargeting lymphocytes against the HER2/neu tumor antigen.
To create chimeric receptors by linking HER2/neu binding elements to an intracellular signaling module.
To demonstrate the expression and potential application of these novel receptors in cellular and stem cell contexts.

Main Methods:

Developed two new molecules: a single-chain variable fragment (scFv) from an anti-HER2 antibody and a single-chain TCR (scTCR) from a HER2-reactive TCR.
Linked HER2 binding elements to an intracellular signaling module specific to the T cell pathway.
Demonstrated expression of these chimeric receptors in various cell lines and hematopoietic stem cells (HSCs).

Main Results:

Successfully engineered two novel chimeric receptors with specificity for HER2/neu.
Confirmed expression of these receptors in multiple cell lines and HSCs.
Showed potential for these receptors to be expressed in diverse cell types derived from repopulating HSCs in a transplant setting.

Conclusions:

The developed chimeric receptors are novel tools for retargeting lymphocytes against HER2/neu-expressing tumors.
Expression in HSCs indicates potential for generating immune cells with engineered specificity.
These molecules will advance research into the immune function of retargeted hematopoietic cells for cancer therapy.